A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
about
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A Phase Ib pharmacokinetic stu ...... irinotecan-based chemotherapy.
@en
A Phase Ib pharmacokinetic stu ...... h capecitabine and oxaliplatin
@nl
type
label
A Phase Ib pharmacokinetic stu ...... irinotecan-based chemotherapy.
@en
A Phase Ib pharmacokinetic stu ...... h capecitabine and oxaliplatin
@nl
prefLabel
A Phase Ib pharmacokinetic stu ...... irinotecan-based chemotherapy.
@en
A Phase Ib pharmacokinetic stu ...... h capecitabine and oxaliplatin
@nl
P2093
P2860
P50
P1476
A Phase Ib pharmacokinetic stu ...... irinotecan-based chemotherapy
@en
P2093
Dal-Hyun Kim
Hye Ryun Kim
Jae Kyung Roh
Kyung Soo Park
Tae Won Kim
Yong Sang Hong
Yoon Jung Lee
P2860
P2888
P304
P356
10.1007/S10637-010-9625-X
P577
2010-12-29T00:00:00Z
P6179
1031874657